BOSTON--(BUSINESS WIRE)--Jun. 1, 2016--
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing
drugs to treat cancer, today announced that the company will present at
the following upcoming investor conferences:
The Jefferies 2016 Healthcare Conference on Thursday, June 9 at 9:30
a.m. ET at the Grand Hyatt in New York City
The JMP Securities Life Sciences Conference on Wednesday, June 22 at
10:00 a.m. ET at the St. Regis in New York City
The company will also participate in the 2016 Citi European Healthcare
Conference being held June 21-22 at Stirling Square in London.
Live audio webcasts of the presentations will be available on the
company’s website at www.verastem.com.
Archived presentations will be available for 90 days.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on
discovering and developing drugs to improve outcomes for patients with
cancer. Our product candidates utilize a multi-faceted approach to treat
cancer by reducing cancer stem cells, enhancing anti-tumor immunity, and
modulating the local tumor microenvironment. Our most advanced clinical
product candidates are the Focal Adhesion Kinase inhibitors, VS-6063 and
VS-4718, and the dual PI3K/mTOR inhibitor, VS-5584. For more
information, please visit www.verastem.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160601005438/en/
Source: Verastem, Inc.
Brian Sullivan, 781-292-4214